このエントリーをはてなブックマークに追加


ID 71387
フルテキストURL
著者
Takeuchi, Yasuto Department of Gastroenterology, Okayama University Hospital
Sue, Masahiko Department of Gastroenterology, Okayama University Hospital
Miyake, Nozomi Department of Gastroenterology, Okayama University Hospital
Adachi, Takuya Department of Gastroenterology, Okayama University Hospital
Onishi, Hideki Department of Gastroenterology, Okayama University Hospital
Kawanaka, Miwa Department of Gastroenterology, Okayama University Hospital
Takaki, Akinobu Department of Gastroenterology, Okayama University Hospital Kaken ID publons researchmap
Nouso, Kazuhiro Department of Gastroenterology, Okayama City Hospital ORCID Kaken ID publons researchmap
Kariyama, Kazuya Department of Gastroenterology, Okayama City Hospital
Nakamura, Shinichiro Department of Gastroenterology, Japanese Red Cross Himeji Hospital
Tanaka, Emi Department of Gastroenterology, Japanese Red Cross Himeji Hospital
Tada, Toshifumi Department of Gastroenterology, Kobe University Hospital
Yasunaka, Tetsuya Department of Gastroenterology, Fukuyama City Hospital
Kuwaki, Kenji Department of Gastroenterology, Okayama Saiseikai General Hospital Kaken ID
Toshimori, Junichi Department of Gastroenterology, Japanese Red Cross Okayama Hospital
Iwado, Shota Department of Gastroenterology, Hiroshima City Hospital
Moriya, Akio Department of Gastroenterology, Mitoyo General Hospital
Hagihara, Hiroaki Department of Gastroenterology, Sumitomo Besshi Hospital
Takabatake, Hiroyuki Department of Gastroenterology, Kurashiki Central Hospital
Sakata, Masahiro Department of Gastroenterology, Fukuyama Medical Center
Otsuka, Motoyuki Department of Gastroenterology, Okayama University Hospital
抄録
Background
Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline resectable (BR) classification combined with the barcelona clinic liver cancer (BCLC) staging system to identify patients most likely to benefit from conversion following atezolizumab plus bevacizumab (ATZ/BEV) therapy.
Methods
In this multicenter retrospective study, 532 patients with unresectable HCC treated with ATZ/BEV were categorized using the BR classification and stratified according to the BCLC stage. We evaluated objective response rate (ORR), conversion rate, and overall survival (OS) and carried out multivariate logistic regression analysis to identify predictors of conversion.
Results
Conversion therapy was performed in 5.9% of patients. Among those with BCLC-C HCC, the conversion rate was significantly higher in BR1 HCC than in BR2 HCC (15.2% vs. 2.0% and p < 0.01), and BR1 status was independently associated with conversion (odds ratio 7.0). Patients with BCLC-C/BR1 staging showed the highest ORR (45.0%) and favorable OS after conversion (p = 0.015). In contrast, the BR classification had limited predictive value in patients with BCLC-B HCC. Notably, downstaging from BR1 to resectable status was more common than from BR2, suggesting higher conversion feasibility.
Conclusions
Integrating BR classification with BCLC staging identified BCLC-C/BR1 patients as optimal candidates for conversion therapy after ATZ/BEV treatment. These findings support incorporating anatomical and oncological criteria into systemic strategies to enable curative interventions in advanced HCC.
キーワード
atezolizumab plus bevacizumab
barcelona clinic liver cancer stage
borderline resectable classification
conversion therapy
hepatocellular carcinoma
発行日
2026-02-09
出版物タイトル
Hepatology Research
巻
56巻
号
5号
出版者
Wiley
開始ページ
830
終了ページ
839
ISSN
1386-6346
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2026 The Author(s).
論文のバージョン
publisher
PubMed ID
DOI
CRID
関連URL
isVersionOf https://doi.org/10.1111/hepr.70138
ライセンス
https://creativecommons.org/licenses/by-nc/4.0/
Citation
Takeuchi, Yasuto, Masahiko Sue, Nozomi Miyake, et al. 2026. “ Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab,” Hepatology Research: 56. no. 5), 830–839. https://doi.org/10.1111/hepr.70138.
助成情報
22H02828: 膵癌における反復配列RNAの機能解析と治療選択最適化への応用 ( 独立行政法人日本学術振興会 / Japan Society for the Promotion of Science )
23fk0210092: 慢性炎症を背景とした肝発癌の機序解明と肝癌高危険群の囲い込み法の開発 ( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
23fk0210133: RNAを中心に据えたB型肝炎の病態解明と完全排除法開発 ( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
23fk0310506: B型肝炎ウイルスのゲノム活性化・複製機序解明と創薬・標的因子同定に資する研究 ( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )